Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
Syndax Pharmaceuticals (SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has scheduled its third quarter 2024 financial results announcement and business update for November 5, 2024. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Management will discuss financial results and provide business updates during the call, which will be accessible via phone or webcast. A replay will be available on the company's website for 90 days following the call.
Syndax Pharmaceuticals (SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata sulle terapie contro il cancro, ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale per il 5 novembre 2024. L'azienda ospiterà una conferenza telefonica e un webcast audio dal vivo alle 16:30 ET lo stesso giorno. Il management discuterà i risultati finanziari e fornirà aggiornamenti aziendali durante la chiamata, che sarà accessibile tramite telefono o webcast. Una registrazione sarà disponibile sul sito web dell'azienda per 90 giorni dopo la chiamata.
Syndax Pharmaceuticals (SNDX), una empresa biofarmacéutica en etapa comercial centrada en terapias contra el cáncer, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial para el 5 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo de audio a las 4:30 p.m. ET el mismo día. La dirección discutirá los resultados financieros y proporcionará actualizaciones empresariales durante la llamada, que será accesible por teléfono o webcast. Una grabación estará disponible en el sitio web de la empresa durante 90 días después de la llamada.
Syndax Pharmaceuticals (SNDX)는 암 치료에 중점을 둔 상업 단계의 생명공학 회사로, 2024년 3분기 재무 결과 발표 및 비즈니스 업데이트를 2024년 11월 5일로 예정하였습니다. 회사는 같은 날 오후 4:30 ET에 전화 회의 및 라이브 오디오 웹캐스트를 개최할 예정입니다. 경영진은 전화 회의 중에 재무 결과를 논의하고 비즈니스 업데이트를 제공할 것입니다. 회의 후 90일 동안 회사 웹사이트에서 다시 들으실 수 있습니다.
Syndax Pharmaceuticals (SNDX), une entreprise biopharmaceutique en phase commerciale axée sur les thérapies contre le cancer, a programmé l'annonce de ses résultats financiers du troisième trimestre 2024 et une mise à jour des affaires pour le 5 novembre 2024. L'entreprise organisera une conférence téléphonique et une diffusion audio en direct à 16h30 ET le même jour. La direction discutera des résultats financiers et fournira des mises à jour commerciales lors de l'appel, qui sera accessible par téléphone ou par webcast. Un enregistrement sera disponible sur le site Web de l'entreprise pendant 90 jours suivant l'appel.
Syndax Pharmaceuticals (SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Krebstherapien konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 und ein Geschäftsupdate für den 5. November 2024 angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast abhalten. Das Management wird die Finanzergebnisse besprechen und während des Gesprächs Geschäftsinformationen bereitstellen, die entweder telefonisch oder über den Webcast zugänglich sind. Eine Aufzeichnung wird 90 Tage nach dem Anruf auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, November 5, 2024 to discuss the Company's financial results and provide a business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax3Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX3Q24.cfm
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2024-financial-results-and-host-conference-call-and-webcast-on-november-5-2024-302286420.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When will Syndax Pharmaceuticals (SNDX) release Q3 2024 earnings?
How can investors access Syndax's (SNDX) Q3 2024 earnings call?
How long will Syndax's (SNDX) Q3 2024 earnings call replay be available?
